Do oral ovulation induction agents offer benefits in women 38 to 43 years of age undergoing insemination cycles?

Naama Steiner, Jacob Ruiter-Ligeti, Jacob Ruiter‐Ligeti, Russell Frank, Maryam Al Shatti, Ahmad Badeghiesh, Keren Rotshenker-Olshinka, William Buckett, Michael H. Dahan
European journal of obstetrics, gynecology, and reproductive biology · 2021 · vol. 258 , pp. 273–277 · doi:10.1016/j.ejogrb.2021.01.012 · PMID:33486239 · W3120219503
Observational OA: closed CC0
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-08 ⓘ

This study investigated whether oral ovulation induction agents provide any benefit to women aged 38-43 undergoing insemination cycles.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVE: To compare the success of ovulation induction using oral agents versus gonadotropins (GTs) in women ≥38 years old. STUDY DESIGN: A retrospective cohort study was performed including all first to third stimulated IUI cycles conducted after the age of 38 years in a single academic fertility center between 01/2011 and 03/2018. RESULTS: A total of 1596 IUI cycles were included. 240 cycles were with clomiphene citrate (CC), 176 letrozole cycles and 1180 gonadotropin (GTs) cycles. The GTs group were older (p < 0.001), had lower antral follicular count (p < 0.001), and thicker endometrium (p < 0.001) compared to the oral agent groups. The letrozole group had a less mature follicles (p = 0.004) at the time of triggering compared to the other groups. No difference in pregnancy or clinical pregnancy rates was observed after controlling for confounders when comparing the 3-groups. 5 multiple pregnancies occurred, all in the GTs group. The groups were subdivided by age; 38-39 years old (N = 750) and 40-43 years old (N = 846). Nevertheless, no statistical difference was observed in pregnancy rates and clinical pregnancy rates between oral agents and GTs when controlling for the confounding effects among women at age 38-39 (p = 0.47, p = 1.0; respectively) and among women 40-43-years-old (p = 0.16, p = 1.0; respectively). CONCLUSIONS: Clearly costs of oral agents are lower and they are more patient friendly than GTs, therefore oral agents should be first line for ovarian stimulation and IUI in women 38-43-years of age.

My notes (saved in your browser only)

MeSH descriptors

Fertility Agents, Female Infertility, Female Adult Clomiphene Clomiphene Female Humans Insemination, Artificial Ovulation Induction Pregnancy Pregnancy Rate Retrospective Studies

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (1)

References (15)

Source provenance

openalex
last seen: 2026-05-11T05:40:41.230350+00:00
pubmed
last seen: 2026-10-08T21:29:46.384990+00:00
License: CC0 · commercial use OK